Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 1/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 5/20 | 0.34 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30606585 | 1.00 | CFD (0.36) | CFDOPRL1ADRB2KMT2AGLA | |
| SCHEMBL30606590 | 0.83 | ADRB2 (0.33) | ADRB2 | |
| SCHEMBL26599045 | 0.83 | ADRB2 (0.33) | ADRB2 | |
| SCHEMBL26666993 | 0.83 | CFD (0.40) | CFD | |
| SCHEMBL26599037 | 0.80 | CFD (0.35) | CFDOPRL1KMT2AGLAHTT | |
| SCHEMBL30606591 | 0.80 | CFD (0.35) | CFDOPRL1KMT2AGLAHTT | |
| SCHEMBL26599069 | 0.78 | CFD (0.37) | CFDOPRL1KMT2AGLAHTT | |
| SCHEMBL30606528 | 0.78 | CFD (0.37) | CFDOPRL1KMT2AGLAHTT | |
| SCHEMBL30606498 | 0.76 | CFD (0.34) | CFDOPRL1KMT2AP2RX7 | |
| SCHEMBL26599149 | 0.76 | CFD (0.34) | CFDOPRL1KMT2AP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4511355-A2 | EFFECTIVE MEANS TO MODULATE NMDA RECEPTOR-MEDIATED TOXICITY | FundaMental Pharma GmbH (DE) | 2025-02-26 | — | — | EP | disclosed |
| WO-2023203254-A2 | EFFECTIVE MEANS TO MODULATE NMDA RECEPTOR-MEDIATED TOXICITY | FUNDAMENTAL PHARMA GMBH (DE) | 2023-10-26 | — | — | WO | disclosed |